EOLS
Price
$6.78
Change
-$0.25 (-3.56%)
Updated
Nov 19, 01:39 PM (EDT)
Capitalization
456.98M
112 days until earnings call
Intraday BUY SELL Signals
NBIX
Price
$138.02
Change
-$0.61 (-0.44%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
13.82B
84 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EOLS vs NBIX

Header iconEOLS vs NBIX Comparison
Open Charts EOLS vs NBIXBanner chart's image
Evolus
Price$6.78
Change-$0.25 (-3.56%)
Volume$100
Capitalization456.98M
Neurocrine Biosciences
Price$138.02
Change-$0.61 (-0.44%)
Volume$16.85K
Capitalization13.82B
EOLS vs NBIX Comparison Chart in %
EOLS
Daily Signal:
Gain/Loss:
NBIX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
EOLS vs. NBIX commentary
Nov 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EOLS is a Hold and NBIX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 19, 2025
Stock price -- (EOLS: $7.05 vs. NBIX: $138.62)
Brand notoriety: EOLS and NBIX are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: EOLS: 103% vs. NBIX: 127%
Market capitalization -- EOLS: $456.98M vs. NBIX: $13.82B
EOLS [@Pharmaceuticals: Generic] is valued at $456.98M. NBIX’s [@Pharmaceuticals: Generic] market capitalization is $13.82B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EOLS’s FA Score shows that 0 FA rating(s) are green whileNBIX’s FA Score has 0 green FA rating(s).

  • EOLS’s FA Score: 0 green, 5 red.
  • NBIX’s FA Score: 0 green, 5 red.
According to our system of comparison, NBIX is a better buy in the long-term than EOLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EOLS’s TA Score shows that 6 TA indicator(s) are bullish while NBIX’s TA Score has 3 bullish TA indicator(s).

  • EOLS’s TA Score: 6 bullish, 4 bearish.
  • NBIX’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, EOLS is a better buy in the short-term than NBIX.

Price Growth

EOLS (@Pharmaceuticals: Generic) experienced а +0.86% price change this week, while NBIX (@Pharmaceuticals: Generic) price change was -5.89% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.86%. For the same industry, the average monthly price growth was -6.64%, and the average quarterly price growth was +28.04%.

Reported Earning Dates

EOLS is expected to report earnings on Mar 11, 2026.

NBIX is expected to report earnings on Feb 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-3.86% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NBIX($13.8B) has a higher market cap than EOLS($457M). NBIX YTD gains are higher at: 1.553 vs. EOLS (-36.141). NBIX has higher annual earnings (EBITDA): 613M vs. EOLS (-33.58M). NBIX has more cash in the bank: 1.12B vs. EOLS (61.7M). EOLS has less debt than NBIX: EOLS (155M) vs NBIX (428M). NBIX has higher revenues than EOLS: NBIX (2.68B) vs EOLS (278M).
EOLSNBIXEOLS / NBIX
Capitalization457M13.8B3%
EBITDA-33.58M613M-5%
Gain YTD-36.1411.553-2,327%
P/E RatioN/A33.08-
Revenue278M2.68B10%
Total Cash61.7M1.12B6%
Total Debt155M428M36%
FUNDAMENTALS RATINGS
EOLS vs NBIX: Fundamental Ratings
EOLS
NBIX
OUTLOOK RATING
1..100
1871
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
7658
SMR RATING
1..100
10053
PRICE GROWTH RATING
1..100
6247
P/E GROWTH RATING
1..100
10034
SEASONALITY SCORE
1..100
5014

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBIX's Valuation (73) in the Biotechnology industry is in the same range as EOLS (93) in the Pharmaceuticals Major industry. This means that NBIX’s stock grew similarly to EOLS’s over the last 12 months.

NBIX's Profit vs Risk Rating (58) in the Biotechnology industry is in the same range as EOLS (76) in the Pharmaceuticals Major industry. This means that NBIX’s stock grew similarly to EOLS’s over the last 12 months.

NBIX's SMR Rating (53) in the Biotechnology industry is somewhat better than the same rating for EOLS (100) in the Pharmaceuticals Major industry. This means that NBIX’s stock grew somewhat faster than EOLS’s over the last 12 months.

NBIX's Price Growth Rating (47) in the Biotechnology industry is in the same range as EOLS (62) in the Pharmaceuticals Major industry. This means that NBIX’s stock grew similarly to EOLS’s over the last 12 months.

NBIX's P/E Growth Rating (34) in the Biotechnology industry is significantly better than the same rating for EOLS (100) in the Pharmaceuticals Major industry. This means that NBIX’s stock grew significantly faster than EOLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EOLSNBIX
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
59%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
70%
Momentum
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
53%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
63%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
57%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
55%
Advances
ODDS (%)
Bullish Trend 7 days ago
79%
Bullish Trend 14 days ago
72%
Declines
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 2 days ago
56%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
77%
Aroon
ODDS (%)
Bullish Trend 2 days ago
89%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
EOLS
Daily Signal:
Gain/Loss:
NBIX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GDXU169.553.78
+2.28%
MicroSectors™ Gold Miners 3X Lvrgd ETN
BKCH73.461.54
+2.14%
Global X Blockchain ETF
FLQS41.270.07
+0.17%
Franklin US Small Cap Mltfctr Idx ETF
BLGR28.25-0.30
-1.07%
Bluemonte Large Cap Growth ETF
DESK37.67-1.30
-3.33%
VanEck Office and Commercial REIT ETF

EOLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EOLS has been loosely correlated with LNTH. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if EOLS jumps, then LNTH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EOLS
1D Price
Change %
EOLS100%
+1.44%
LNTH - EOLS
37%
Loosely correlated
+1.92%
AMRX - EOLS
32%
Poorly correlated
-0.04%
PRGO - EOLS
31%
Poorly correlated
-1.25%
NBIX - EOLS
30%
Poorly correlated
-3.44%
KNSA - EOLS
30%
Poorly correlated
-0.29%
More